The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...
GMT] In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in ...
Whether you're a fan of pizza-gobbling mutant turtles or the pistol-wielding witch on the Switch, 2022 was a breakout year for action games. Whether you're a fan of pizza-gobbling mutant turtles or ...
("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...
Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback